RESEARCH TRIANGLE PARK, N.C.,
May 3, 2011 /PRNewswire/ -- Talecris
Biotherapeutics Holdings Corp. (NASDAQ: TLCR) held its annual
meeting of stockholders today in Chapel
Hill, N.C., where four proposals were submitted to, and
approved by, stockholders.
Stockholders elected three directors to the company's Board of
Directors to hold office for a three-year term until the annual
meeting of stockholders in 2014, and until their successors are
elected and qualified. The three directors are W. Brett Ingersoll, Lawrence D. Stern and Ruedi E. Waeger, PhD.
Stockholders also ratified the appointment of
PricewaterhouseCoopers LLP as the company's independent,
registered, public accounting firm for the fiscal year ending
December 31, 2011.
In a pair of advisory and non-binding votes, stockholders
approved the compensation of the company's named executive officers
and recommended holding an advisory vote every three years on
compensation of the company's named executive officers.
A replay of the meeting will be available beginning at
1 p.m. EDT and will remain accessible
until May 10, 2011, by dialing
1-888-286-8010 (domestic) or 1-617-801-6888 (international).
The pass code is 86974301. The webcast of the meeting call
will be archived on the Investor Relations section of
http://www.talecris.com.
About Talecris Biotherapeutics: Inspiration.
Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and
biotechnology company that discovers, develops and produces
critical care treatments for people with life-threatening disorders
in a variety of therapeutic areas including immunology,
pulmonology, neurology and hemostasis. For more information, please
visit: www.talecris.com.
SOURCE Talecris Biotherapeutics Holdings Corp.